Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance

Journal of Chemotherapy

Volumn 28, Issue 4, 2016, Pages 297-303

  Laishram, Shakti ^a   Anandan, Shalini ^a   Devi, Bakthavatchalam Yamuna ^a   Elakkiya, Munusamy ^a   Priyanka, Babu ^a   Bhuvaneshwari, Thukkaram ^a   Peter, John Victor ^a   Subramani, Kandasmy ^a   Balaji, Veeraraghavan ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Acinetobacter baumannii; Carbapenem resistant; Colistin; OXA 48 like; Klebsiella pneumoniae; Meropenem; NDM; Sulbactam; Synergy

Indexed keywords

CARBAPENEM; CARBAPENEMASE; COLISTIN; MEROPENEM; SULBACTAM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION INDEX; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; SULBACTAM; THIENAMYCINS;

EID: 84979730434     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1080/1120009X.2016.1143261     Document Type: Article

References (39)

1. P.J.Bergen, Z.P.Bulman, S.Saju, J.B.Bulitta, C.Landersdorfer, A.Forrest, et al. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy. 2015;35:34–42.
2. C.Mammina, C.Bonura, F.Di Bernardo, A.Aleo, T.Fasciana, C.Sodano, et al. 2012. Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011. Euro Surveill, 2012;17(33):pii 20248.
3. T.Bogdanovich, J.M.Adams-Haduch, G.B.Tian, M.H.Nguyen, E.J.Kwak, C.A.Muto, et al. Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis. 2011;53:373–6.
4. M.L.Mezzatesta, F.Gona, C.Caio, V.Petrolito, D.Sciortino, A.Sciacca, et al. Outbreak of KPC- 3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitals. Clin Microbiol Infect. 2011;17:1444–7.
5. A.Toth, I.Damjanova, E.Puskas, L.Janvari, M.Farkas, A.Dobak, et al. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur J Clin Microbiol Infect Dis. 2010;29:765–9.
6. K.Kontopoulou, E.Protonotariou, K.Vasilakos, M.Kriti, A.Koteli, E.Antoniadou, et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin. J Hosp Infect. 2010;76:70–3.
7. G.Goel, L.Hmar, M.Sarkar De, S.Bhattacharya, M.Chandy. Colistin-resistant Klebsiella pneumoniae: report of a cluster of 24 cases from a new oncology center in eastern India. Infect Control Hosp Epidemiol. 2014;35:1076–7.
8. Y.Doi, D.L.Paterson. Carbapenemase-producing Enterobacteriaceae. Semin Respir Crit Care Med. 2015;36:74–84.
9. Clinical and Laboratory Standards Institute. [CLSI document M100-S23]Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
10. L.S.Gracia. Clinical microbiology procedures handbook. 2nd (update) edn.Santa Monica, CA: ASM Press; 2007.
11. P.Nordmann, L.Poirel, L.Dortet. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2012;18:1503–7.
12. L.Dortet, L.Poirel, C.Errera, P.Nordmann. CarbAcineto NP test for rapid detection of carbapenemase-producing Acinetobacter spp. J Clin Microbiol. 2014;52:2359–64.
13. L.Poirel, T.R.Walsh, V.Cuvillier, P.Nordmann. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70:119–23.
14. H.Yigit, A.M.Queenan, G.J.Anderson, A.Domenech-Sanchez, J.W.Biddle, C.D.Steward, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45:1151–61.
15. L.Poirel, M.Castanheira, A.Carrer, C.P.Rodriguez, R.N.Jones, J.Smayevsky, et al. OXA-163, an OXA-48-related class D beta-lactamase with extended activity toward expanded-spectrum cephalosporins. Antimicrob Agents Chemother. 2011;55:2546–51.
16. P.Nordmann, A.E.Boulanger, L.Poirel. NDM-4 metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli. Antimicrob Agents Chemother. 2012;56:2184–6.
17. S.M.Amudhan, U.Sekar, K.Arunagiri, B.Sekar. OXA beta-lactamase-mediated carbapenem resistance in Acinetobacter baumannii. Indian J Med Microbiol. 2011;29:269–74.
18. A.P.Magiorakos, A.Srinivasan, R.B.Carey, Y.Carmeli, M.E.Falagas, C.G.Giske, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.
19. J.Y.Choi, Y.S.Park, C.H.Cho, S.Y.Shin, Y.G.Song, D.Yong, et al. Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii. Clin Microbiol Infect. 2004;10:1098–01.
20. W.C.Ko, H.C.Lee, S.R.Chiang, J.J.Yan, J.J.Wu, C.L.Lu, et al. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother. 2004;53:393–5.
21. J.Y.Song, S.Y.Kee, I.S.Hwang, Y.B.Seo, H.W.Jeong, W.J.Kim, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007;60:317–22.
22. W.H.Sheng, J.T.Wang, S.Y.Li, Y.C.Lin, A.Cheng, Y.C.Chen, et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis. 2011;70:380–6.
23. L.Principe, A.Capone, A.Mazzarelli, S.D'Arezzo, E.Bordi, A.Di Caro, et al. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection. Microb Drug Resist. 2013;19:407–14.
24. P.Pongpech, S.Amornnopparattanakul, S.Panapakdee, S.Fungwithaya, P.Nannha, C.Dhiraputra, et al. Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii. J Med Assoc Thai. 2010;93:161–71.
25. A.Cikman, M.R.Ceylan, M.Parlak, M.K.Karahocagil, M.Berktas. [Evaluation of colistin- ampicillin/sulbactam combination efficacy in imipenem-resistant Acinetobacter baumannii strains]. Mikrobiyol Bul. 2013;47:147–51.
26. O.Zusman, T.Avni, L.Leibovici, A.Adler, L.Friberg, T.Stergiopoulou, et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013;57:5104–11.
27. T.Y.Tan, T.P.Lim, W.H.Lee, S.Sasikala, L.Y.Hsu, A.L.Kwa. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob Agents Chemother. 2011;55:436–8.
28. R.L.White, D.S.Burgess, M.Manduru, J.A.Bosso. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996;40:1914–8.
29. M.G.Jernigan, E.G.Press, M.H.Nguyen, C.J.Clancy, R.K.Shields. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2012;56:3395–8.
30. M.Souli, P.D.Rekatsina, Z.Chryssouli, I.Galani, H.Giamarellou, K.Kanellakopoulou. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?Antimicrob Agents Chemother. 2009;53:2133–5.
31. W.Santimaleeworagun, P.Wongpoowarak, P.Chayakul, S.Pattharachayakul, P.Tansakul, K.W.Garey. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health. 2011;42:890–900.
32. C.J.Clancy, L.Chen, J.H.Hong, S.Cheng, B.Hao, R.K.Shields, et al. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother. 2013;57:5258–65.
33. J.H.Hong, C.J.Clancy, S.Cheng, R.K.Shields, L.Chen, Y.Doi, et al. Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems. Antimicrob Agents Chemother. 2013;57:2147–53.
34. C.J.Clancy, B.Hao, R.K.Shields, L.Chen, D.S.Perlin, B.N.Kreiswirth, et al. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC- producing Klebsiella pneumoniae strains with various ompK36 genotypes. Antimicrob Agents Chemother. 2014;58:3521–5.
35. G.Biancofiore, C.Tascini, M.Bisa, G.Gemignani, M.L.Bindi, A.Leonildi, et al. Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report. Minerva Anestesiol. 2007;73:181–5.
36. C.H.Lee, Y.F.Tang, L.H.Su, C.C.Chien, J.W.Liu. Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia. Microb Drug Resist. 2008;14:233–7.
37. A.Oliva, M.T.Mascellino, A.Cipolla, A.D'Abramo, A.De Rosa, S.Savinelli, et al. Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen. Int J Infect Dis. 2015;33:132–4.
38. J.Perrott, V.H.Mabasa, M.H.Ensom. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Ann Pharmacother. 2010;44:557–64.
39. S.Jaruratanasirikul, S.Sriwiriyajan, J.Punyo. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3- hour infusion or bolus injection. Antimicrob Agents Chemother. 2005;49:1337–9.